Get the Weekly Intelligence Brief — top committee picks every Sunday.
SRRK · NASDAQ · STOCK

Scholar Rock Holding (SRRK) Stock Analysis

Healthcare Updated October 10, 2026
$42.22
52W $27.07 – $61.76
46/100
$5.06B
-12.7
0.62
AI Committee Verdict
Watch
46/100
Conviction: Contested · 50% agreement · 6 analysts
+2.5%
-3.8%
0.66:1
Contested

Is SRRK Bullish or Bearish?

Mixed. Innellis AI committee rates Scholar Rock Holding Corporation (SRRK) Watch with a composite score of 46/100 , based on 6 analysts with 50% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +14.31 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -5.69 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
Insufficient data for bull case.
Bear Case
  • Price-to-book of 18.3x prices in significant intangible value — Value
  • ROE of only -159.1% -- cheap may mean cheap for a reason — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • RSI at 23 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 26.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
46/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 99%
of 192 Healthcare peers
Value Analyst neutral
43 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 18.3x prices in significant intangible value
Growth Analyst bearish
35 / 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bearish
38 / 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 23 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 26.4% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 45.7 to 45.7.

Analyst-level changes:
  • Risk Analyst: +1 bearish signal(s).
  • Technical Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
22.8
Oversold
MACD Histogram
-0.583
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$40.62
Resistance
$43.27
Bollinger %B
0.10
Inside Bands
Price vs Moving Averages
EMA 9
$44.28 Below
EMA 21
$47.17 Below
EMA 50
$49.76 Below
EMA 200
$47.76 Below

Fundamental Analysis

Valuation
64
Growth
54
Profitability
0
Financial Health
92
Cash Flow
15
Valuation
P/E Ratio -12.7×
P/B Ratio 21.71×
PEG Ratio 1.16
Dividend Yield 0.00%
52W High $61.76
52W Low $27.07
Quality & Growth
ROE -15395.4%
ROA -9348.6%
Gross Margin 0.0%
Operating Margin 0.0%
Revenue Growth YoY —
Debt / Equity 0.80
AI Fundamental Assessment
P/E ratio of -12.7 (inexpensive relative to a 15-40x range); Price-to-book of 21.7x; PEG ratio of 1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -154.0%; Return on assets of -93.5%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 7.02 (healthy short-term liquidity); Debt-to-equity of 0.80; Free cash flow per share is negative (-2.27); Most recent quarter beat estimates by 2.0%; EPS growth decelerating (+5.7% -> -1.2% QoQ); Analyst estimates rising over recent quarters
Get the Full SRRK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime